Actively Recruiting
Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)
Led by Xiangtan Central Hospital · Updated on 2024-07-01
1990
Participants Needed
1
Research Sites
229 weeks
Total Duration
On this page
Sponsors
X
Xiangtan Central Hospital
Lead Sponsor
S
Second Xiangya Hospital of Central South University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The primary objective of this study is to investigate the hemoglobin change and association between hemoglobin change and readmissions due to heart failure, and all-cause death in patients with heart failure treated with dapagliflozin or placebo.
CONDITIONS
Official Title
Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female between the ages of 18 and 100 years.
- Elevated NT-proBNP or BNP levels on admission.
- Ejection fraction of 50% or less.
- New York Heart Association (NYHA) class II, III, or IV symptoms.
You will not qualify if you...
- Treatment with SGLT2 inhibitor during the past 3 months or previous intolerance to an SGLT2 inhibitor.
- Severe (eGFR <30 mL/min/1.73 m² by CKD-EPI), unstable or rapidly progressing kidney disease at randomization.
- Pregnant or breastfeeding female patients.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xiangtan Central Hospital
Xiangtan, Hunan, China, 411100
Actively Recruiting
Research Team
J
Jianping Zeng, Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here